Vanguard Group Inc Armata Pharmaceuticals, Inc. Transaction History

Vanguard Group Inc

$4.96 Trillion
Q1 2024

A detailed history of Vanguard Group Inc transactions in Armata Pharmaceuticals, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 159,209 shares of ARMP stock, worth $402,798. This represents 0.0% of its overall portfolio holdings.

Number of Shares

159,209

Previous 145,078 9.74%

Holding current value

$402,798

Previous $470,000 41.49%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$2.81 - $4.18 $39,708 - $59,067	14,131 Added 9.74%	159,209 $665,000
Q4 2023 Feb 14, 2024	BUY	$1.95 - $3.24 $105,512 - $175,313	54,109 Added 59.48%	145,078 $470,000
Q3 2023 Nov 14, 2023	BUY	$1.1 - $4.35 $34,186 - $135,193	31,079 Added 51.89%	90,969 $272,000
Q2 2023 Aug 14, 2023	BUY	$1.14 - $1.7 $3,087 - $4,603	2,708 Added 4.74%	59,890 $68,000
Q1 2023 May 15, 2023	BUY	$1.1 - $3.58 $14,725 - $47,925	13,387 Added 30.57%	57,182 $95,000

Q4 2022 Feb 10, 2023	SELL	$0.94 - $3.28 $228,941 - $798,860	-243,555 Reduced 84.76%	43,795 $54,000
Q3 2022 Nov 14, 2022	BUY	$3.12 - $4.92 $44,304 - $69,864	14,200 Added 5.2%	287,350 $1.21 Million
Q1 2022 May 13, 2022	BUY	$3.9 - $6.32 $40,560 - $65,728	10,400 Added 3.96%	273,150 $1.34 Million
Q4 2021 Feb 14, 2022	BUY	$2.96 - $5.86 $278,512 - $551,379	94,092 Added 55.79%	262,750 $1.44 Million
Q3 2021 Nov 12, 2021	BUY	$3.55 - $4.14 $4,544 - $5,299	1,280 Added 0.76%	168,658 $610,000
Q2 2021 Aug 13, 2021	BUY	$3.89 - $4.87 $651,100 - $815,130	167,378 New	167,378 $665,000

Others Institutions Holding ARMP

# of Institutions

Shares Held

1.42M

Call Options Held

200

Put Options Held

View Full List

About Armata Pharmaceuticals, Inc.

Ticker ARMP
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,144,700
Market Cap $91.4M
Description
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus ...

More about ARMP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Armata Pharmaceuticals, Inc. Transaction History